דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים: arrivent.com (AVBP)

לוגו של חברה ציבורית ArriVent Corp (AVBP)

ArriVent BioPharma, Inc (AVBP) is scaling its business through patent protection of innovative formulas, minimizing costs across global sales. The year-over-year percentage change in sales volume for the LTM demonstrates revenue dynamics, where 0.00 represents the current metric. The approval of furmonertinib will provide the company with pricing power due to the therapy's uniqueness, although final trial costs and commercial risks are putting pressure on capital.

AVBP - צמיחת מכירות משנה לשנה (TTM) ArriVent BioPharma Inc בטווח 23.11.2025 - 18.11.2026

ArriVent (AVBP) - פילוחי מדדים ודוחות פיננסיים

- מחיר שוק ויעדי מחיר של אנליסטים:
ניתוח כל מדדי החברה:ArriVent Corp - AVBP
מוצרים מיוצרים של ArriVent BioPharma Inc

ArriVent BioPharma, Inc (AVBP) focuses on the development of the furmonertinib inhibitor for the treatment of non-small cell lung cancer, where commercial success depends on FDA approval and licensing agreements. By analyzing the year-over-year revenue dynamics over 12 months, an investor can observe the percentage change in rolling revenue, allowing for a real-time assessment of business scaling rates while accounting for volatility risks during sharp spikes in performance metrics.